BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc. the leader in lung cancer diagnostics, today announced the appointment of internationally recognized lung cancer expert, James Jett, M.D., as Chief Medical Officer. Dr. Jett joins Steven Springmeyer, M.D. as co-CMO to support all aspects of the Company’s research, development and commercialization efforts. Today’s news comes as Biodesix continues to drive adoption of the recently launched Nodify XL2™ proteomic nodule classifier.
Dr. Jett joins Biodesix from Oncimmune Ltd., where he served as the Chief Medical Officer. His career includes work as a Professor of Medicine at the Mayo Medical School and the University of Pittsburgh. Dr. Jett has also served as a consultant for the National Cancer Institute in Bethesda, and he was the Editor in Chief of the Journal of Thoracic Oncology from 2006-2013. His work on academic editorial boards includes Chest, Respiratory Medicine, and the American Journal of Respiratory and Critical Care Medicine.
In addition to all aspects of the company, Dr. Jett and Dr. Springmeyer will combine expertise to focus on advancing the Biodesix lung cancer and nodule management programs. Springmeyer joined the company from Integrated Diagnostics (acquired by Biodesix in 2018) and Jett from Oncimmune (notice of acquisition in 2019).
“Biodesix is a natural continuation of my gratifying career as a physician. I believe that the future of patient care in oncology and pulmonology should be designed and innovated with the patient experience as the highest priority,” said Dr. Jett. “I see Biodesix as a company leading the way in developing diagnostic tools that can help guide physicians and their patients to the most appropriate individual course of action.”
“We continue to build a portfolio of best-in class lung nodule diagnostic tests along with a team of world class clinical experts,” said Scott Hutton, chief operating officer, Biodesix. “We take lung cancer personally and by attracting the brightest minds in solving these complex diagnostic challenges we will continue to have a positive impact on physicians and their patients.”
Biodesix is a lung cancer diagnostic solutions company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The company develops diagnostic tests addressing important clinical questions by combining simple blood draws and multi-omics with the power of artificial intelligence. Biodesix is the first company to offer three best-in class tests for patients with lung cancer, and multiple pipeline tests including one with the potential to identify patients who may benefit from immunotherapies. The Biodesix Lung Reflex® strategy integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours. The Nodify XL2™ nodule test, evaluates the risk of malignancy, enabling physicians to triage patients to the most appropriate course of action. Biodesix also partners with the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges. For more information about Biodesix, please visit www.biodesix.com.